VERTEX PHARMACEUTICALS INC / MA Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) of $3.85 million for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-02.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveSettledWithCash · last filed 2013-08-02
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for the quarter ending 2013-06-30 was $3.85M, a 3.33% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $3.57M, a 3.07% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $3.72M, a 0.80% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $3.73M, a 1.11% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for fiscal 2012 was $14.85M, a 0.34% decline from fiscal 2011.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for fiscal 2011 was $14.90M, a 0.98% increase from fiscal 2010.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for fiscal 2010 was $14.76M, a 1.11% decline from fiscal 2009.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, settled with cash (deprecated 2013-01-31) for fiscal 2009 was $14.92M, a 6.47% increase from fiscal 2008.
| Period end | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 3 month | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 6 month | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 9 month | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 12 month | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 84 month | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 96 month | Restructuring Reserve, Settled With Cash (Deprecated 2013-01-31) 108 month |
|---|---|---|---|---|---|---|---|
| 2013-06-30 | $3.85M 10-Q · filed 2013-08-02 | $7.42M 10-Q · filed 2013-08-02 | $11.14M derived: sum of 3 quarters · filed 2013-08-02 | $14.86M derived: sum of 4 quarters · filed 2013-08-02 | |||
| 2013-03-31 | $3.57M 10-Q · filed 2013-05-08 | $7.29M derived: sum of 2 quarters · filed 2013-05-08 | $11.02M derived: sum of 3 quarters · filed 2013-05-08 | $14.74M derived: sum of 4 quarters · filed 2013-08-02 | |||
| 2012-12-31 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $7.44M derived: sum of 2 quarters · filed 2013-03-01 | $11.17M derived: sum of 3 quarters · filed 2013-08-02 | $14.85M 10-K · filed 2013-03-01 | $163.70M 10-K · filed 2013-03-01 | ||
| 2012-09-30 | $3.73M 10-Q · filed 2012-11-06 | $7.45M derived: sum of 2 quarters · filed 2013-08-02 | $11.14M 10-Q · filed 2012-11-06 | $14.88M derived: sum of 4 quarters · filed 2013-08-02 | |||
| 2012-06-30 | $3.73M 10-Q · filed 2013-08-02 | $7.41M 10-Q · filed 2013-08-02 | $11.16M derived: sum of 3 quarters · filed 2013-08-02 | $14.84M derived: sum of 4 quarters · filed 2013-08-02 | |||
| 2012-03-31 | $3.69M 10-Q · filed 2013-05-08 | $7.43M derived: sum of 2 quarters · filed 2013-05-08 | $11.12M derived: sum of 3 quarters · filed 2013-05-08 | $14.85M derived: sum of 4 quarters · filed 2013-05-08 | |||
| 2011-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $7.43M derived: sum of 2 quarters · filed 2013-03-01 | $11.17M derived: sum of 3 quarters · filed 2013-03-01 | $14.90M 10-K · filed 2013-03-01 | $148.84M 10-K · filed 2012-02-22 | ||
| 2011-09-30 | $3.69M 10-Q · filed 2012-11-06 | $7.42M derived: sum of 2 quarters · filed 2012-11-06 | $11.16M 10-Q · filed 2012-11-06 | $14.75M derived: sum of 4 quarters · filed 2013-03-01 | |||
| 2011-06-30 | $3.74M 10-Q · filed 2012-08-08 | $7.47M 10-Q · filed 2012-08-08 | $11.06M derived: sum of 3 quarters · filed 2013-03-01 | $14.82M derived: sum of 4 quarters · filed 2013-03-01 | |||
| 2011-03-31 | $3.74M 10-Q · filed 2012-05-10 | $7.33M derived: sum of 2 quarters · filed 2013-03-01 | $11.08M derived: sum of 3 quarters · filed 2013-03-01 | $14.83M derived: sum of 4 quarters · filed 2013-03-01 | |||
| 2010-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $7.34M derived: sum of 2 quarters · filed 2013-03-01 | $11.10M derived: sum of 3 quarters · filed 2013-03-01 | $14.76M 10-K · filed 2013-03-01 | $133.94M 10-K · filed 2011-02-17 | ||
| 2010-09-30 | $3.75M 10-Q · filed 2011-11-03 | $7.51M derived: sum of 2 quarters · filed 2011-11-03 | $11.17M 10-Q · filed 2011-11-03 | $14.56M derived: sum of 4 quarters · filed 2012-02-22 | |||
| 2010-06-30 | $3.75M 10-Q · filed 2011-08-09 | $7.42M 10-Q · filed 2011-08-09 | $10.81M derived: sum of 3 quarters · filed 2012-02-22 | $14.58M derived: sum of 4 quarters · filed 2012-02-22 | |||
| 2010-03-31 | $3.66M 10-Q · filed 2011-05-06 | $7.06M derived: sum of 2 quarters · filed 2012-02-22 | $10.83M derived: sum of 3 quarters · filed 2012-02-22 | $14.81M derived: sum of 4 quarters · filed 2012-02-22 | |||
| 2009-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $7.17M derived: sum of 2 quarters · filed 2012-02-22 | $11.15M derived: sum of 3 quarters · filed 2012-02-22 | $14.92M 10-K · filed 2012-02-22 | |||
| 2009-09-30 | $3.77M 10-Q · filed 2010-10-28 | $7.76M derived: sum of 2 quarters · filed 2010-10-28 | $11.53M 10-Q · filed 2010-10-28 | ||||
| 2009-06-30 | $3.98M 10-Q · filed 2010-08-03 | $7.76M 10-Q · filed 2010-08-03 | |||||
| 2008-12-31 | $14.02M 10-K · filed 2011-02-17 | ||||||
| 2003-12-31 | $17.82M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |